These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25126322)

  • 1. The impact of healthcare reform on payers' products, provider reimbursement, and member engagement.
    Muppalla S; Capobianco R
    Am Health Drug Benefits; 2010 Jul; 3(4):289-90. PubMed ID: 25126322
    [No Abstract]   [Full Text] [Related]  

  • 2. Payers' Perspectives on Pharmacist-Directed Care in a Community Pharmacy Setting.
    Merrill BS; Tak CR; Feehan M; Munger MA
    Ann Pharmacother; 2019 Sep; 53(9):916-921. PubMed ID: 30895798
    [No Abstract]   [Full Text] [Related]  

  • 3. Interesting times ahead: payers' innovation in the era of healthcare reform.
    Tzeel A
    Am Health Drug Benefits; 2012 Nov; 5(7):408-9. PubMed ID: 24991337
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessing payer perspectives on health information exchange.
    Cross DA; Lin SC; Adler-Milstein J
    J Am Med Inform Assoc; 2016 Mar; 23(2):297-303. PubMed ID: 26142424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in biologic therapies for rheumatoid arthritis: results from a survey of payers and providers.
    Greenapple R
    Am Health Drug Benefits; 2012 Mar; 5(2):83-92. PubMed ID: 24991313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The payers' automation challenge.
    Colby M
    Health Data Manag; 1994 Apr; 2(3):26-30, 32-4. PubMed ID: 10141181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic impact of new active substance status on EU payers' budgets: example of dimethyl fumarate (Tecfidera(®)) for multiple sclerosis.
    Toumi M; Jadot G
    J Mark Access Health Policy; 2014; 2():. PubMed ID: 27226838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between depression and healthcare expenditures among elderly cancer patients.
    Gu D; Morgan RO; Li R; Weber ES; Shen C
    BMC Psychiatry; 2020 Mar; 20(1):131. PubMed ID: 32293366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping US commercial payers' coverage policies for medical interventions.
    Chambers JD; Chenoweth MD; Neumann PJ
    Am J Manag Care; 2016 Sep; 22(9):e323-8. PubMed ID: 27662396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health reform and payment trends don't wait for politicians.
    Bauer JC
    Healthc Financ Manage; 2008 Apr; 62(4):40-2. PubMed ID: 18441969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Who pays? How reimbursement impacts the emergency department.
    Downey L; Zun LS; Burke T; Jefferson T
    J Health Hum Serv Adm; 2014; 36(4):400-16. PubMed ID: 24772689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innovative payer engagement strategies: will the convergence lead to better value creation in personalized medicine?
    Akhmetov I; Bubnov RV
    EPMA J; 2017 Dec; 8(1):5-15. PubMed ID: 28228864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving provider payment models and patient access to innovative medical technology.
    Long G; Mortimer R; Sanzenbacher G
    J Med Econ; 2014 Dec; 17(12):883-93. PubMed ID: 25221929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Private payers and cancer care: land of opportunity.
    Klein I; Kolodziej M
    J Oncol Pract; 2014 Jan; 10(1):15-9. PubMed ID: 24084888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reimbursement of licensed cell and gene therapies across the major European healthcare markets.
    Jørgensen J; Kefalas P
    J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Payers in the Development of Cardiovascular Therapeutics: Misalignment Between Approval and Reimbursement.
    Zannad F; Alonso Garcia MLA; Borer JS; Stough WG; Clutton-Brock T; Rosenberg Y; Packer M
    J Am Coll Cardiol; 2017 Dec; 70(22):2822-2830. PubMed ID: 29191332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative.
    Trosman JR; Weldon CB; Douglas MP; Kurian AW; Kelley RK; Deverka PA; Phillips KA
    J Natl Compr Canc Netw; 2017 Feb; 15(2):219-228. PubMed ID: 28188191
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluating the feasibility and impact of case rate payment for recovery support navigator services: a mixed methods study.
    Torres ME; Brolin M; Panas L; Ritter G; Hodgkin D; Lee M; Merrick E; Horgan C; Hopwood JC; Gewirtz A; De Marco N; Lane N
    BMC Health Serv Res; 2020 Nov; 20(1):1004. PubMed ID: 33143701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging lessons from regional and state innovation in value-based payment reform: balancing collaboration and disruptive innovation.
    Conrad DA; Grembowski D; Hernandez SE; Lau B; Marcus-Smith M
    Milbank Q; 2014 Sep; 92(3):568-623. PubMed ID: 25199900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining and Managing High-Priced Cures: Healthcare Payers' Opinions.
    Yeung K; Suh K; Garrison LP; Carlson JJ
    Value Health; 2019 Jun; 22(6):648-655. PubMed ID: 31198181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.